SynthesisFrontiers in oncology2019

Comparative Efficacy, Safety, and Costs of Sorafenib vs. Sunitinib as First-Line Therapy for Metastatic Renal Cell Carcinoma: A Systematic Review and Meta-Analysis.

Huan Deng et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.